Can-Fite Presents Phase IIa Namodenoson Data In Advanced Pancreatic Cancer, Meeting Primary Safety Endpoint And Showing Encouraging Survival Outcomes
Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated patientsOne second-line patient achieved progression-free survival of 16.39 months and overall
Share
Why It Matters
Can-Fite tested a new cancer medicine and it was safe. Early signs showed some patients lived longer than expected.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.